Patent Application: Janus Kinase Inhibitors by Chiesi Farmaceutici

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Published September 8th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085077A1) filed by Chiesi Farmaceutici S.P.A. The application describes compounds of general formula (I) that inhibit Janus Kinase (JAK) family kinases. These compounds are intended for therapeutic use in treating inflammatory diseases.

View original document View source feed page

What changed

This document is a published patent application from the USPTO for compounds identified as Janus Kinase (JAK) inhibitors. The application, filed by Chiesi Farmaceutici S.P.A., details compounds of general formula (I) and their potential therapeutic uses, particularly for inflammatory diseases such as asthma and COPD. The application includes specific CPC classifications related to heterocyclic derivatives and pharmaceutical compositions.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future intellectual property rights for the assignee and may inform research and development strategies within the pharmaceutical sector. Companies operating in the organic chemistry and pharmaceutical manufacturing space should be aware of this filing for competitive intelligence and potential licensing opportunities.

Source document (simplified)

← USPTO Patent Applications

HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS

Application US20260085077A1 Kind: A1 Mar 26, 2026

Assignee

CHIESI FARMACEUTICI S.P.A.

Inventors

Alessandro ACCETTA, Alberto CUZZOLIN, Fabio RANCATI, Andrea RIZZI, Ivaylo Jivkov ELENKOV, Milan MESIC, Ela RADOŠEVIC

Abstract

The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory diseases including asthma, COPD and other respiratory diseases.